VS-7375 Demonstrates Robust Anti-Tumor Activity Across Advanced KRAS G12D-Mutant Cancers, Highlighted by 50% Confirmed ORR in 2L Pancreatic Ductal Adenocarcinoma and Two Complete Responses in 2L+ Disease (One Confirmed)

VS-7375 was reported to show robust clinical activity with favorable safety and tolerability in KRAS G12D-mutated pancreatic, lung and colorectal cancers. The article provides no response rates, trial phase, or other quantitative results.